Cargando…
EP-7041, a Factor XIa Inhibitor as a Potential Antithrombotic Strategy in Extracorporeal Membrane Oxygenation: A Brief Report
OBJECTIVES: Current approaches to systemic antithrombotic therapy in support of extracorporeal membrane oxygenation are limited and are hampered by both thrombotic and hemorrhagic complications. An alternative approach is needed. DESIGN: Inhibition of coagulation factor XI/activated factor XI is an...
Autores principales: | Pollack, Charles V., Kurz, Michael A., Hayward, Neil J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7498136/ https://www.ncbi.nlm.nih.gov/pubmed/32984829 http://dx.doi.org/10.1097/CCE.0000000000000196 |
Ejemplares similares
-
Extracorporeal membrane oxygenation in children: A brief review
por: Sakurai, Ken, et al.
Publicado: (2022) -
Outcomes of Fungemia in Patients Receiving Extracorporeal Membrane Oxygenation
por: Rosas, Melissa M, et al.
Publicado: (2022) -
Sequence-Dependent Radiosensitization of Histone Deacetylase Inhibitors Trichostatin A and SK-7041
por: Kim, Jin Ho, et al.
Publicado: (2013) -
Bleeding, Thromboembolism, and Clinical Outcomes in Venovenous Extracorporeal Membrane Oxygenation
por: Stokes, John W., et al.
Publicado: (2020) -
A Nationwide Three-Month Education Program for Venoarterial
Extracorporeal Membrane Oxygenation
por: Gao, Sizhe, et al.
Publicado: (2023)